NR3C2 and chronic kidney disease: Although routine aldosterone measurements are uncommon in clinical practice due to complex protocols and impact by disease-modifying drugs,212 implementing aldosterone/MR-targeted therapy at an early stage of TRH and/or CKD is essential if we wish to avoid its CV and renal consequences (Figure 2).